ISSN: 1859 - 2872
Results of adjuvant trastuzumab combined chemotherapy regimen in HER2/neu positive breast cancer patients at Viet Tiep Friendship Hospital
Main Article Content
Keywords
Abstract
Objective: To assess the efficacy and safety of adjuvant chemotherapy in combination with trastuzumab in patients with HER2/-positive breast cancer. Subject and method: This retrospective descriptive study included 42 patients diagnosed with stage I–IIIA HER2-positive breast cancer who underwent either modified radical mastectomy or breast-conserving surgery with axillary lymph node dissection. All patients received adjuvant chemotherapy combined with trastuzumab at Viet Tiep Friendship Hospital between January 2018 and March 2025. Result: The most common age group was 50–59 years (31.0%). The majority of patients were diagnosed at stage II (69.1%). Modified radical mastectomy (Patey procedure) was performed in 88.1% of cases. The 5-year disease-free survival (DFS) rate was 78.6%. Neutropenia occurred in 57.1% of patients, with grade 3-4 neutropenia observed in 31.0%. Febrile neutropenia was reported in 28.6% of cases. No cases of grade 3-4 anemia or thrombocytopenia were reported. There were no treatment-related deaths or discontinuations due to neutropenia. Left ventricular ejection fraction (LVEF) remained stable in all patients, with no recorded decreases exceeding 10%. Conclusion: Adjuvant chemotherapy combined with trastuzumab demonstrated good efficacy with an acceptable toxicity profile.
Article Details
References
2. GLOBOCAN 2022: New Global Cancer Data | UICC. accessed: 05/07/2022.
3. Tạ Văn Tờ và cộng sự (2001) Nghiên cứu thụ thể yếu tố phát triển biểu mô trong ung thư vú bằng nhuộm hóa mô miễn dịch. Tạp chí Y học thành phố Hồ Chí Minh, 5(4), tr. 23-28.
4. Tạ Văn Tờ (2004) Nghiên cứu hình thái học, hóa mô miễn dịch và giá trị của chúng trong ung thư biểu mô tuyến vú. Luận văn Tiến sỹ Y học, Trường đại học Y Hà Nội.
5. Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. ClinBreast Cancer 5(1): 63-69.
6. Slamon D, Eiermann W, Robert N et al (2016) Abstract S5-04: Ten years follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Res 76 (4_Supplement): S5-04.
7. Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075): 1195-1205.
8. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr et al (2014) Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33): 3744-3750.
9. Phùng Thị Huyền, Nguyễn Thị Huyền (2022) Kết quả sống thêm 10 năm ở bệnh nhân ung thư vú dưới 35 tuổi tại Bệnh viện K. Tạp chí Nghiên cứu Y học (Đại học Y Hà Nội) 151(03), tr. 129-138.
Article Sidebar
